CBRE Group
CBRE
356 hedge funds and large institutions have $7.14B invested in CBRE Group in 2013 Q3 according to their latest regulatory filings, with 41 funds opening new positions, 132 increasing their positions, 149 reducing their positions, and 30 closing their positions.
37% more first-time investments, than exits
New positions opened: 41 | Existing positions closed: 30
22% more call options, than puts
Call options by funds: $7.22M | Put options by funds: $5.9M
3% more funds holding
Funds holding: 346 → 356 (+10)
1% less capital invested
Capital invested by funds: $7.19B → $7.14B (-$59M)
11% less repeat investments, than reductions
Existing positions increased: 132 | Existing positions reduced: 149
20% less funds holding in top 10
Funds holding in top 10: 5 → 4 (-1)
Top Buyers
| 1 |
JP Morgan Chase
New York
|
+$87.5M |
| 2 |
Goldman Sachs
New York
|
+$60.7M |
| 3 |
FPP
Findlay Park Partners
London,
United Kingdom
|
+$60.5M |
| 4 |
SFM
Systematic Financial Management
Teaneck,
New Jersey
|
+$43.6M |
| 5 |
Prudential Financial
Newark,
New Jersey
|
+$42.3M |
Top Sellers
CBRE Hedge Fund Activity: Q3 2013 in Review
356 of the 3,084 institutional investors tracked by Wall St. Rank reported a position in CBRE Group (CBRE) for Q3 2013, worth a combined $7.14B — down 0.82% from $7.19B a quarter earlier.
Buyers outnumbered sellers: 41 funds opened new CBRE positions and 30 closed out — a net gain of 11 holders — while 132 added to existing stakes and 149 trimmed.
The largest buyer was JP Morgan Chase, adding an estimated $87.5M. The largest seller was PFM Health Sciences, exiting entirely with an estimated $133M sold.
- 356 institutional investors held CBRE Group (CBRE) as of Q3 2013, up from 346 in Q2 2013.
- Funds reported $7.14B of CBRE Group stock for Q3 2013, down 0.82% quarter-over-quarter.
- 41 funds opened new CBRE Group positions in Q3 2013 and 30 closed out, a net change of +11 holders.
- The largest CBRE Group buyer in Q3 2013 was JP Morgan Chase, an estimated $87.5M added.
- The largest CBRE Group seller in Q3 2013 was PFM Health Sciences, an estimated $133M sold.
Based on aggregated 13F filings for Q3 2013.